Results 1 to 10 of about 4,832 (178)

Benralizumab for the Prevention of COPD Exacerbations [PDF]

New England Journal of Medicine, 2019
The efficacy and safety of benralizumab, an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are not known.In the GALATHEA and TERRANOVA trials, we enrolled patients with COPD (at a ratio of approximately 2:1 on ...
Gérard J Criner, Bartolome R Celli, Christopher E Brightling   +2 more
exaly   +15 more sources

Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis

Frontiers in Pharmacology, 2022
Two types of interleukin (IL)-5 antibody biologics, anti-IL-5 antibodies (mepolizumab) and anti-IL-5α receptor antibodies (benralizumab), are indicated for severe asthma.
Yasuhiko Koga, Makiko Sato, Hiroaki Tsurumaki   +2 more
exaly   +3 more sources

Pharmacoeconomic analysis of using benralizumab for treatment of severe asthma in inpatient and outpatient settings

Фармакоэкономика, 2022
Objective: evaluation of the pharmacoeconomic feasibility of using benralizumab in the form of autoinjector (pen-injector device) in outpatient facilities compared with its use in the form of a syringe in hospital settings for the treatment of severe ...
M. V. Zhuravleva, S. N. Avdeev, Yu. V. Gagarina, T. V. Marin   +3 more
doaj   +2 more sources

Neoplasm Adverse Events Associated With Anti-Type 2 Biologics: An FAERS Database Pharmacovigilance Analysis Study. [PDF]

Cancer Med
ABSTRACT Background Biologics targeting Type 2 immune responses, such as omalizumab (anti‐IgE), dupilumab (anti‐interleukin‐4 receptor alpha, anti‐IL‐4Rα), benralizumab (anti‐IL‐5R), reslizumab, and mepolizumab (anti‐IL‐5), are increasingly used clinically.
Lyu W, Xu R, Chen L, Lei W, Chen C, Liao J, Lin X, Ma R, Wen W, Li H.   +9 more
europepmc   +2 more sources

Comparative efficacy of mepolizumab and benralizumab in severe eosinophilic asthma: a retrospective cohort study [PDF]

BMC Pulmonary Medicine
Purpose This real-world study compared the efficacy and the proportion of patients attaining the criteria constituting clinical remission at 12 months between mepolizumab and benralizumab in patients with severe eosinophilic asthma.
Wei-Chun Huang, Yi-Luen Shen, Wen-Chien Cheng, Chien-Wen Huang, Chia-Hung Chen, Chih- Yen Tu, Wu-Huei Hsu   +6 more
doaj   +2 more sources

Long-term effectiveness and safety of benralizumab in EGPA: a 3-year single-center experience [PDF]

Annals of Medicine
Objectives Benralizumab emerged as a promising treatment option for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the long-term effectiveness and safety of benralizumab in patients with severe asthma and relapsing-refractory ...
Federica Davanzo, Luca Iorio, Marta Codirenzi, Eleonora Fiorin, Gabriella Guarnieri, Alessia Achille, Fulvia Chieco Bianchi, Maria Rita Marchi, Andrea Vianello, Andrea Doria, Roberto Padoan   +10 more
doaj   +2 more sources

Eosinophilic Depletion with Benralizumab, Mepolizumab, and Depemokimab: A Modeling Study [PDF]

Journal of Asthma and Allergy
Pradeep B Lukka,1 Robert C Penland,1 Ari Brekkan,2 Rami Ayoun Alsoud,2 Sherri So,3 David W Boulton1 1Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA ...
Lukka PB, Penland RC, Brekkan A, Ayoun Alsoud R, So S, Boulton DW   +5 more
doaj   +1 more source

Pretreatment Frequency of Circulating Th17 Cells and FeNO Levels Predicted the Real-World Response after 1 Year of Benralizumab Treatment in Patients with Severe Asthma

Biomolecules, 2023
Benralizumab treatment reduces exacerbations and improves symptom control and quality of life in patients with severe eosinophilic asthma. However, the determination of biomarkers that predict therapeutic effectiveness is required for precision medicine.
Yuuki Sandhu, Norihiro Harada, Hitoshi Sasano, Sonoko Harada, Shoko Ueda, Tomohito Takeshige, Yuki Tanabe, Ayako Ishimori, Kei Matsuno, Sumiko Abe, Tetsutaro Nagaoka, Jun Ito, Asako Chiba, Hisaya Akiba, Ryo Atsuta, Kenji Izuhara, Sachiko Miyake, Kazuhisa Takahashi   +17 more
doaj   +1 more source

Safety and efficacy of monoclonal antibodies targeting IL-5 in severe eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials

Health Sciences Review, 2023
Background: Recently, mepolizumab and benralizumab have been approved for the treatment of severe eosinophilic asthma. Objective: Thus, the main objective of the current study was to find out the exact efficacy and safety profile of mepolizumab and ...
Noor Alam, S. Latha, Anoop Kumar
doaj   +1 more source

Effects of anti‐IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real‐life multicentre study (BIONIGE)

Clinical and Translational Allergy, 2022
Background Mepolizumab and benralizumab are clinically effective biological treatments for severe eosinophilic asthmatic patients by hampering eosinophilic inflammation. The effects of these compound on the immunoglobulin (Ig)E T2 component are virtually
Marco Contoli, Pierachille Santus, Francesco Menzella, Cindy Rocchi, Dejan Radovanovic, Federico Baraldi, Chiara Martelli, Serena Casanova, Carlo Barbetta, Claudio Micheletto, Nicola Scichilone, Bianca Beghè, Elisiana Carpagnano, Alberto Papi   +13 more
doaj   +1 more source